李凤娟
2021-12-28
3-1. 教育经历:
2009.08~2012.12,香港中文大学,生物化学专业,理学博士;
2006.09~2009.07,中国科学技术大学,细胞生物学专业,理学硕士;
2002.09~2006.07,河南师范大学,生物科学专业,理学学士。
3-2. 工作经历:
2020.11~至今,北京市心肺血管疾病研究所,副研究员;
2015.06~2020.11,北京市心肺血管疾病研究所,助理研究员;
2012.12~2015.05,北京大学医学部,博士后。
3-3. 主持或参加科研项目(课题)及人才计划项目情况:
1)北京市行业定额项目,基于质谱技术的类固醇激素测定试剂盒临床应用,2020,主持
2)北京市行业定额项目,基于质谱技术的类固醇激素检测临床转化应用,2019,主持
3)国家自然科学基金青年基金,脂肪组织中芳香化酶参与调节脂肪再分布的机制, 2014/01-2016/12,主持
4)国家自然科学基金,IL-33/ST2信号通路抑制炎症小体激活减少主动脉夹层发生的机制研究, 2019/01-2022/12,参与。
5)国家自然科学基金重大研究计划集成项目,基于多模态成像的心肌梗死后微循环代谢稳态失衡的机制研究,2019/01-2021/12,100万,参与
6)国家重点研发计划精准医学研究重点专项,2017YFC0908401 ,“中国重大疾病与罕见病临床与生命组学数据库” 2017/10-2020/12,参与
7)国家重点研发计划精准医学研究,2016YFC0903002,“主动脉瘤/夹层的精准预测体系研究” 2016/07 -2019/06,参与
8)北京市科学技术委员会生命科学领域前沿研究项目,Z171100000417002 ,“基于代谢产物的急性心肌梗死分子分型标准研究”,2017/01-2019/12,参与。
3-4.代表性论著
1. Wenjie Yin, Fengjuan Li, Xin Tan, Huimin Wang, Wenxi Jiang, Xue Wang, Sijin Li, Yanbo Zhang, Qinghua Han, Yuan Wang*, Jie Du*. Plasma ceramides and cardiovascular events in hypertensive patients at high cardiovascular risk. American Journal of Hypertension. 2021 Jul 7;hpab10.
2. Wenxi Jiang, Xue Wang, Pei Gao, Fengjuan Li, Ke Lu, Xin Tan, Shuai Zheng, Wang Pei, Meiyu An, Xi Li, Rong Hu, Yongliang Zhong, Junming Zhu, Jie Du, Yuan Wang*. Association of IL1R1 Coding Variant with Plasma level Soluble ST2 and Risk of Aortic Dissection. Frontiers in Cardiovascular Medicine. 2021 Aug 2;8:710425.
3. Bingbing Ke, Xin Tan, Lu Ren, Yangkai Fan, Yixin Zhang, Fengjuan Li, Qiqi Sun, Tong Liu, Lixin Jia, Yuan Wang*, Jie Du*. Dysregulated aldosterone, a component of rennin-angiotensin system, predicts risk of mortality and re-hospitalization in heart failure with preserved ejection fraction. SCIENCE CHINA Life Sciences.2021 Jul 8. doi: 10.1007
4. Xin Tan, Fengjuan Li, Xue Wang, Yuan Wang*. Quantitation and clinical evaluation of plasma aldosterone by ultra-performance liquid chromatography–mass spectrometry. J Chromatogr A. 2019 Aug 13:460456.
5. Fengjuan Li, Tsz Yan Wong, Shu-mei Lin, Simon Chow, Wing-hoi Cheung, Franky L.Chan, Shiuan Chen, Lai K. Leung*. Co-administrating luteolin minimizes the side effects of the aromatase inhibitor letrozole. 2014. Journal of Pharmacology and Experimental Therapeutics. 351:270–277.
6. Tsz Yan Wong, Fengjuan Li, Shu-mei Lin, Franky L Chan, Shiuan Chen and Lai K Leung*. 2014. Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice. BMC Cancer. 14:426. (共同第一作者)
7. Fengjuan Li, Simon Chow, Wing-hoi Cheung, Franky L. Chan, Shiuan Chen, Lai K. Leung*. 2013. The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer. The Journal of Nutritional Biochemistry. 24(6):1112-6
8. Fengjuan Li, Lan Ye, Shu-mei Lin, Lai K. Leung*. 2011. Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7. Molecular and Cellular Endocrinology. 344:51–58
9. Fengjuan Li, Wenjuan Tan, Zhanfang Kang, Chi-Wai Wong*. 2010. Tocotrienol enriched palm oil prevents atherosclerosis through modulating the activities of peroxisome proliferators-activated receptors. Atherosclerosis. 211:278–282
3-5. 授权发明专利
1)25-羟维生素D在制备大动脉炎患者疾病活动性评判试剂盒中的应用(ZL 201810300884.0)
2)醛固酮在制备用于评估心力衰竭患者发生不良事件风险的试剂盒中的应用(专利号201810358307.7)
3)支链氨基酸检测物在制备主动脉夹层患者术后预后风险评估试剂盒中的应用 (专利号201810353368.4)
4)神经酰胺在制备用于评估心力衰竭患者发生不良事件风险的试剂盒中的应用(专利号201910326903.1)
5)一种用于鉴别诊断冠心病患者斑块稳定性的数据处理装置、系统(专利号202011403463.4)
6) 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用(专利号202110784768.2)
7)儿茶酚胺类物质在制备用于预测高血压高危患者心血管事件风险的试剂盒中的应用(专利号202111025286.5)